Latest Insider Transactions at Xeris Biopharma Holdings, Inc. (XERS)
This section provides a real-time view of insider transactions for Xeris Biopharma Holdings, Inc. (XERS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Xeris Biopharma Holdings, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Xeris Biopharma Holdings, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2022
|
Steven Pieper Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
750
-0.05%
|
$1,500
$2.11 P/Share
|
|
Jan 31
2022
|
Kenneth Erland Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,307
-0.52%
|
$4,614
$2.11 P/Share
|
|
Jan 31
2022
|
Beth Hecht Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,448
-0.29%
|
$8,896
$2.11 P/Share
|
|
Jan 31
2022
|
John Patrick Shannon Jr Director |
SELL
Payment of exercise price or tax liability
|
Direct |
7,497
-0.31%
|
$14,994
$2.11 P/Share
|
|
Jan 29
2022
|
Steven Pieper Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,460
-0.21%
|
$6,920
$2.11 P/Share
|
|
Jan 29
2022
|
Kenneth Erland Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,497
-1.67%
|
$14,994
$2.11 P/Share
|
|
Jan 29
2022
|
Beth Hecht Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,037
-0.9%
|
$28,074
$2.11 P/Share
|
|
Jan 29
2022
|
John Patrick Shannon Jr Director |
SELL
Payment of exercise price or tax liability
|
Direct |
15,692
-0.65%
|
$31,384
$2.11 P/Share
|
|
Jan 03
2022
|
Steven Prestrelski Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+11.63%
|
-
|
|
Jan 03
2022
|
Paul R Edick Director |
BUY
Grant, award, or other acquisition
|
Direct |
600,000
+29.88%
|
-
|
|
Jan 03
2022
|
John Patrick Shannon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+28.77%
|
-
|
|
Jan 03
2022
|
Beth Hecht Officer |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+34.0%
|
-
|
|
Jan 03
2022
|
Kenneth Erland Johnson Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+31.14%
|
-
|
|
Jan 03
2022
|
Steven Pieper Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+33.97%
|
-
|
|
Nov 15
2021
|
Paul R Edick Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+37.43%
|
$40,000
$2.28 P/Share
|
|
Nov 12
2021
|
John Patrick Shannon Jr Director |
BUY
Open market or private purchase
|
Direct |
60,000
+14.16%
|
$120,000
$2.1 P/Share
|
|
Nov 11
2021
|
Paul R Edick Director |
BUY
Open market or private purchase
|
Direct |
200,000
+19.84%
|
$400,000
$2.08 P/Share
|
|
Nov 11
2021
|
John Patrick Shannon Jr Director |
BUY
Open market or private purchase
|
Direct |
40,000
+11.63%
|
$80,000
$2.09 P/Share
|
|
Nov 10
2021
|
Steven Pieper Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+12.01%
|
$50,000
$2.0 P/Share
|
|
Oct 05
2021
|
Beth Hecht Officer |
BUY
Grant, award, or other acquisition
|
Direct |
206,366
+48.29%
|
-
|
|
Oct 05
2021
|
Kenneth Erland Johnson Officer |
BUY
Grant, award, or other acquisition
|
Direct |
89,583
+48.33%
|
-
|
|
Oct 05
2021
|
Jeffrey W Sherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,378
+50.0%
|
-
|
|
Oct 05
2021
|
John P. Schmid Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,659
+50.0%
|
-
|
|
Oct 05
2021
|
Steven Pieper Officer |
BUY
Grant, award, or other acquisition
|
Direct |
158,108
+47.97%
|
-
|
|
Oct 05
2021
|
Steven Prestrelski Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
494,780
+34.09%
|
-
|
|
Oct 05
2021
|
John Patrick Shannon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
263,829
+46.14%
|
-
|
|
Oct 05
2021
|
Paul R Edick Director |
BUY
Grant, award, or other acquisition
|
Indirect |
13,430
+50.0%
|
-
|
|
Oct 05
2021
|
Paul R Edick Director |
BUY
Grant, award, or other acquisition
|
Direct |
608,064
+45.16%
|
-
|
|
Oct 05
2021
|
John Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
478,312
+50.0%
|
-
|
|
Oct 05
2021
|
Garheng Kong Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,170
+50.0%
|
-
|